Table 1. IC50 Values of Novel Compound Series (APTs) in a Range of Mammary Carcinoma (MC) Cell Linesa.
| cells |
||||||||
|---|---|---|---|---|---|---|---|---|
| MCF7 | T47D | BT474 | BT549 | MDA-MB-231 | MDA-MB-468 | HCC70 | BT20 | |
| entry | IC50 ± SD (μM) | IC50 ± SD (μM) | IC50 ± SD (μM) | IC50 ± SD (μM) | IC50 ± SD (μM) | IC50 ± SD (μM) | IC50 ± SD (μM) | IC50 ± SD (μM) |
| 3a | 22.6 ± 7.94 | 19.8 ± 3.44 | 18.1 ± 2.95 | 28.6 ± 7.43 | 12.9 ± 4.28 | 22.2 ± 9.63 | 19.1 ± 9.2 | NV ± NV |
| 3b | NV ± NV | NV ± NV | NV ± NV | 27.4 ± 5.32 | 23 ± 3.75 | NV ± NV | NV ± NV | 31.4 ± 8.82 |
| 3c | 16.5 ± 3.62 | 12.6 ± 2.64 | 28.4 ± 7.49 | 15.3 ± 4.25 | 22.5 ± 7.48 | 13.7 ± 3.42 | 7.55 ± 2.32 | 20.4 ± 6.93 |
| 3d | NV ± NV | NV ± NV | NV ± NV | 24.5 ± 4.38 | 44.4 ± 12.6 | 18.6 ± 4.37 | 38.9 ± 9.63 | 29.5 ± 8.31 |
| 3e | 12.9 ± 2.49 | 9.92 ± 3.54 | 14.7 ± 3.21 | 4.92 ± 0.97 | 5.34 ± 0.72 | 7.55 ± 1.04 | 5.96 ± 1.17 | 9.62 ± 0.89 |
| 3f | 17.5 ± 3.89 | 15.3 ± 4.24 | 21.8 ± 4.67 | 14 ± 2.66 | 9.72 ± 2.01 | 5.83 ± 1.31 | 8.02 ± 3.99 | 13.7 ± 2.31 |
| 3g | NV ± NV | NV ± NV | NV ± NV | NV ± NV | NV ± NV | NV ± NV | NV ± NV | NV ± NV |
| 3h | 29.1 ± 6.97 | 31.6 ± 8.38 | 41.3 ± 10.3 | 19.4 ± 4.28 | NV ± NV | NV ± NV | 35.8 ± 11.3 | 31.4 ± 9.26 |
| 3i | 16.5 ± 4.69 | 22.5 ± 4.09 | 37.4 ± 11.6 | 32.5 ± 10.4 | NV ± NV | 12.5 ± 4.91 | 21.6 ± 5.05 | 14.3 ± 3.93 |
| 3j | 38.5 ± 10.5 | NV ± NV | 57.3 ± 11.4 | 17.9 ± 2.08 | 27.6 ± 8.31 | 34.4 ± 8.46 | NV ± NV | 27.1 ± 5.94 |
| 3k | NV ± NV | NV ± NV | 24.5 ± 11 | 42.2 ± 9.31 | 34.9 ± 12 | 19 ± 2.31 | 22.6 ± 8.15 | 39.5 ± 14.8 |
| 3l | NV ± NV | NV ± NV | NV ± NV | NV ± NV | NV ± NV | NV ± NV | NV ± NV | NV ± NV |
a
NV, no value; IC50 values were calculated using GraphPad Prism software (version 5.0). Cell viability was measured using AlamarBlue cell viability assay.